OptiRTP Schedules Meetings with Two Pharmaceutical Companies to Discuss Co-Therapy Applications
OptiRTP has scheduled meetings with two established New Zealand pharmaceutical companies in January 2026 to discuss potential co-therapy applications for its Optimum Bio Sound Therapy (OBST) neuromodulation platform.
The discussions will focus on how OBST could be integrated as a supportive therapy alongside existing pharmaceutical treatments, with initial emphasis on improving patient tolerability and wellbeing outcomes.
Both companies have international distribution networks and experience across multiple therapeutic areas. OptiRTP has identified oncology supportive care as an initial area of focus, where non-invasive technologies may help address unmet needs in patient comfort during treatment.
The meetings represent OptiRTP’s first formal discussions with pharmaceutical companies regarding co-therapy integration.
About OptiRTP
OptiRTP (Return to Play) is a New Zealand-based biotech company. Its core technology, OBST (Optimum Bio Sound Therapy), has 352,000+ documented therapy hours with zero serious adverse events reported. OBST is an FDA-registered Class I medical device, 510(k)-exempt (registration and listing, not FDA clearance or approval), that uses dynamic, patterned acoustic neuromodulation via the auditory pathway, with a proposed mechanism involving modulation of central autonomic regulatory networks associated with sleep, pain, recovery and stress regulation. Drug-free and non-invasive, used passively during sleep or rest through a tablet and earbuds. Users can follow recovery markers on their own wearable.
